When Eli Lilly reports its financial results early Thursday, investors will be looking for the company to press its advantage in the booming weight-loss drug market. Competitor Novo Nordisk has fallen behind Lilly, as Lilly’s weight-loss shot Zepbound has seized a commanding majority of U.S. obesity prescriptions over Novo’s Wegovy.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.